Skip to main content
. 2024 Jun 7;11(4):947–962. doi: 10.1007/s40744-024-00675-0

Fig. 3.

Fig. 3

ADD of OGC during the follow-up period (a), and time to OGC discontinuation in patients with ADD >0 mg at index (b). ADD average daily dose, CI confidence interval, IS immunosuppressant, OGC oral glucocorticoid, SLE systemic lupus erythematosus